SymbolCAI
NameCARIS LIFE SCIENCES, INC.
SectorHEALTH CARE
RegionNorth America
IndustryMedical Specialities
Address750 W. JOHN CARPENTER FREEWAY,SUITE 800, IRVING, Texas, 75039, United States
Telephone(866) 771-8946
Fax
Email
Websitewww.carislifesciences.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK
Description

Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Our current commercial product portfolio is focused on oncology and consists of MI Profile, our tissue-based molecular profiling solution that has generated the majority of our revenue to date, and Caris Assure, our novel, universal blood-based molecular profiling solution that was broadly launched in the first quarter of 2024 for therapy selection.

Additional info from NASDAQ:
Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Our current commercial product portfolio is focused on oncology and consists of MI Profile, our tissue-based molecular profiling solution that has generated the majority of our revenue to date, and Caris Assure, our novel, universal blood-based molecular profiling solution that was broadly launched in the first quarter of 2024 for therapy selection.

2026-04-23 07:25

New Form ARS - Caris Life Sciences, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0002019410-26-000034 <b>Size:</b> 18 MB

Read more
2026-04-23 07:24

New Form DEFA14A - Caris Life Sciences, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0002019410-26-000033 <b>Size:</b> 2 MB

Read more
2026-04-23 07:24

New Form DEF 14A - Caris Life Sciences, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0002019410-26-000032 <b>Size:</b> 5 MB

Read more
2026-04-20 12:30

Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026

Read more
2026-04-17 12:30

Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center

Read more
2026-04-07 14:21

New Form SCHEDULE 13G/A - Caris Life Sciences, Inc. <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0000315066-26-000715 <b>Size:</b> 11 KB

Read more
2026-04-02 20:28

(35% Negative) CARIS LIFE SCIENCES, INC. (CAI) Announces Business Combination

Read more
2026-03-25 12:30

Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026

Read more
2026-03-11 12:30

Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting

Read more